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Background: This study was designed to investigate whether stepwise tapering of remifentanil at the end of
surgery could decrease postoperative pain scores and requirements of rescue analgesics after remifentanil-desflurane
anesthesia in patients with thyroidectomy.
Methods: Sixty two patients undergoing thyroidectomy under general anesthesia were randomly allocated into two
groups. All patients were anesthetised with desflurane and high-dose remifentanil. Remifentnail was infused at the rate
of 0.3 μg/kg/min until the end of surgery in patients of the control group (group A) whereas remifentanil was tapered
gradually from 0.3 to 0.1 μg/kg/min until the end of surgery for at least 30 minutes in patients with group B. Pain scores
(0–100 numerical rating scale, NRS), rescue analgesic requirements and adverse events were assessed at 30 min, 2 h,
6 h, 12 h, and 24 h after operation.
Results: There was a significant decrease in pain scores at 30 min (20 [0–80] vs. 50 [0–100], P = 0.002) and 2 h
(30 [10–60] vs. 40 [20–80], P = 0.018) after surgery in group B compared with group A. In addition, rescue analgesics are
less required in group B than in group A postoperatively (2 [1-3] vs. 3 [2,3], P = 0.039). There were no significant
differences in adverse events between the two groups.
Conclusions: Tapering of remifentanil at the end of surgery decreased postoperative pain scores immediately
after thyroidectomy with desflurane and high-dose remifentanil anesthesia.
Trial registration: Clinical Research information Service (CRiS, registration number KCT0000589).
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Opioids are commonly used supplements during general
anesthesia to reduce requirement of anesthetics and to
attenuate sympathetic response to noxious stimuli [1].
Among various opioids, remifentanil, a selective μ-opioid
agonist, is widely administered due to its rapid onset,
short acting period and predictable rapid recovery [1].
However, remifentanil infusion during anesthesia has
been associated with increased early postoperative pain
and rescue analgesics due to the development of opioid
induced hyperalgesia and acute opioid tolearance [2,3].* Correspondence: jinaryu@lycos.co.kr
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unless otherwise stated.This could be a challenge for postoperative pain control
and thereby result in increase of postoperative analgesic
requirements [2,4,5].
The mechanism underlying hyperalgesia after opioid
infusion is still unclear. The animal experimental results
showed that both peripheral and central changes in
nociceptive processing are involved in this process [6].
Central sensitization through activation of the N-methyl-
D-aspartate (NMDA) receptors is considered to be re-
sponsible for opioid induced hyperalgesia [7,8]. Excita-
tory amino acids such as glutamate, aspartate, and
substance P are released from excitatory synapse mem-
branes through central sensitization and then activate
postsynaptic NMDA receptors [9]. The recent study
showed that remifentanil induced rapid and persistent
increases in NMDA responses at clinically relevantis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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showed that abrupt withdrawal from μ opioid receptor
induced long-term potentiation at the synapse of the
pain pathways, which is related with opioid induced
hyperalgesia [11].
Several pharmacologic methods including NMDA an-
tagonists, nonsteroidal anti-inflammatory drugs (NSAIDs)
and alpha agonists have been investigated to prevent opi-
oid induced hyperalgesia. Besides pharmacologic preven-
tions, the authors hypothesized that stepwise tapering of
high-dose remifentanil at the end of surgery could prevent
long-term potentiation at synapses of the pain pathways
[11] and thus diminish postoperative pain and rescue
analgesics during postoperative period. In this study, the
effect of intraoperative tapering of remifentanil on post-
operative pain and rescue analgesics was investigated in




The protocol of this prospective, randomised, and
single-blind investigation was approved by the Institu-
tional Review Board of Kangbuk Samsung Hospital
(IRB No. KBC12145) and then registered with the
Clinical Research information Service (CRiS, registra-
tion number KCT0000589). Informed consent was ob-
tained from each patient. A total of 62 American
Society of Anesthesiologist (ASA) physical status I-II
patients, aged 19–70 years, and scheduled for thyroid-
ectomy under general anesthesia from November 2012
to January 2013 were enrolled. Patients with hyper-
sensitivity or allergy with opioids, alcohol or opioids
abuse, chronic pain, or psychiatric disease were ex-
cluded from the study. Patients were instructed with
the use of numerical rating scale (NRS, 0 = no pain to
100 = most severe pain) at the preoperative visit.
Anesthesia
All patients were premedicated with i.v. 0.03 mg/kg mid-
azolam and i.m. glycopyrrolate 0.2 mg 30 minutes before
arriving at the operating room. In the operating room,
standard monitors (electrocardiogram, noninvasive blood
pressure, pulse oximetry and capnography) and spectral
entropy for monitoring depth of anesthesia were applied.
Anesthesia was induced with i.v. 5 mg/ kg thiopental,
0.3 μg/kg/min remifentanil and desflurane 6 vol% followed
by 0.6 mg/kg rocuronium to facilitate endotracheal intub-
ation. Maintenance of anesthesia consisted of desflurane
3.0-6.0% (end-tidal concentration) with medical air in
oxygen (FiO2 = 0.5) and remifentanil to maintain spec-
tral entropy value of 40–60. Patients were mechanically
ventilated to maintain an end-tidal concentration of carbondioxide between 35–40 mmHg throughout the surgery.
Muscle relaxation was achieved with 0.15 mg/ kg rocuro-
nium to maintain 1–2 twitches in response to train-of-four
stimulation of the ulnar nerve. Esophageal temperature was
monitored and maintained at 36-37 °C throughout the op-
eration using a warming pad. At the end of the surgery,
desflurane and remifentanil administration were discontin-
ued and muscle relaxation was antagonized with i.v.
0.01 mg/ kg glycopyrrolate and 0.04 mg/kg neostigmine.
Tracheal extubation was done after patients’ respond to
the verbal command and adequate spontaneous ventila-
tion. Patients were transferred to the post-anesthesia care
unit (PACU) until they fulfill discharge criteria (moderate
Aldrete score > 9) [12] and then moved to the ward.Intervention and randomization
Randomisation was performed before induction of
anesthesia by an independent anesthesiologist responsible
for patient allocation. Computer-generated randomization
code (Random Allocation Software Version 1.0) with
opaque envelopes containing sequential number was used
for randomisation. Patients were allocated to one of the
two groups. Patients in group A (control group without
tapering of remifentanil) were maintained with 0.3 μg/kg/
min remifentanil until the end of surgery. In group B
(experimental group with tapering of remifetanil),
remifentanil was stepwise tapered (0.3 μg/kg/min for
10 minutes→ 0.2 μg/kg/min for 10 minutes→ 0.1 μg/
kg/min for at least 10 minutes) at least for 30 minutes
before the end of surgery by the anesthesiologist who
is in charge of the patients. Patients and outcome as-
sessors were blinded to group assignment.Outcome measures
Patients’ characteristics including age, gender, weight,
height, BMI, ASA physical class, total dose of remifen-
tanil, and information on surgery were collected. The
primary outcome was the postoperative pain. Patients
were asked to evaluate their level of postoperative pain
at 30 min, 2 h, 6 h, 12 h, and 24 h postoperatively using
NRS by blinded outcome assessors.
Secondary outcomes were information on the rescue
analgesic, the concentration of desflurane and awaken-
ing time (the time interval from remifentanil discon-
tinuation to extubation). An i.v. bolus dose of ketorolac
(30 mg) was administered as a rescue analgesic for the
patient with pain scores > 30. The number of the rescue
analgesic and the time interval from the discontinu-
ation of the remifentanil to the first analgesic require-
ment was also observed. Episodes of postoperative
nausea, vomiting and other adverse effects such as shiv-
ering, dizziness, headache, or drowsiness were recorded
postoperatively.
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In a preliminary study, pain scores in 10 patients with-
out tapering of remifentanil were 50 (25) at postopera-
tive 2 h. Reduction the mean pain scores of 20 by the
titration of remifentanil was considered to be clinically
important. Twenty six patients in each group (power of
80% and type I error of 5%) was calculated with the ana-
lysis using sample size software (PASS 2005®, NCSS,
USA). Assuming a 20% dropout rate, the final sample
size was determined to be 31 patients per group.
Test of normality and analysis of data were performed
using SPSS version 15.0 for Windows (SPSS, Chicago,
IL, USA). Mann–Whitney test was used to compare pain
scores, the end-tidal concentration of desflurane, awak-
ening time and the time to the first analgesic require-
ment between the two groups. Chi-square test or Fisher
exact test was used to analyze categorical variables (the
number of rescue analgesics and adverse events). The
correlation between the end-tidal concentration of des-
flurane at the stop of remifentanil and awakening time
was analyzed with Spearman’s rho test. Data are presentedFigure 1 Consort flow diagram. Seventy three patients were assessed fo
(9 patients) and patient refusals (2 patients). Sixty two patients were random
Five patients (4 patients from group A and 1 patient from group B) were e
hypotension, re-operation and the use of NSAID on the day of operation.as median (range) or count (n). Two-sided P-values
of < 0.05 were considered statistically significant.
Results
Seventy three patients were assessed for eligibility and
11 patients were excluded because of exclusion criteria
(9 patients) and patient refusals (2 patients). Sixty two
patients were randomized for the study and 57 patients
were included in the final analysis. Five patients (4 pa-
tients from group A and 1 patient from group B) were
excluded during the study period for protocol violations,
intraoperative hypotension, re-operation and the use of
NSAID on the day of operation (Figure 1). Patients and
surgical characteristics are presented in the Table 1.
Patients in group B reported significantly less pain
than did those in group A 30 min (20 [0–80] vs. 50
[0–100], P = 0.002) and 2 h (30 [10–60] vs. 40 [20–80],
P = 0.018) after surgery (Table 2). Additionally, rescue
analgesics were less frequently required in group B than
in group A (2 [1-3] vs. 3 [2,3], P = 0.039, Table 2). There
is no statistically significance in the time intervals fromr eligibility and 11 patients were excluded because of exclusion criteria
ized for the study and 57 patients were included in the final analysis.
xcluded during the study period for protocol violations, intraoperative






Age (years) 44 (21-63) 42 (29-66)
Male/female (%) 14 (52)/13 (48) 15 (50)/15 (50)
Weight (kg) 66 (46-92) 69 (49-92)
Height (cm) 164 (145-180) 166 (148-183)
BMI 25(18-33) 25 (20-31)
ASA physical class (I/II) 19 (70)/8 (30) 23 (77)/7 (23)
Indication of thyroidectomy, n,(%)
Thyroid cancer 25 (93) 28(93)
Thyroid nodule 2 (7) 2 (7)
Duration of operation (min) 83 (40-160) 79 (50-175)
Duration of anesthesia (min) 120 (75-155) 112 (70-200)
Remifentanil dose (mg) 1.8 (1.2-2.7) 1.7 (0.9-3.3)
Type of Operation
Hemithyroidectomy 1 (4) 3 (10)
Total thyroidectomy 1 (4) 0 (0)
Hemithyroidectomy with neck dissection 6 (22) 4 (13)
Total thyroidectomy with neck dissection 19 (70) 23 (77)
Values are given as median (range) or number of patients (%). A group: no
tapering group, B group: tapering group. BMI: body mass index.
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tion of the first rescue analgesic between the two groups
(P = 0.742, Table 2).
No significant difference was observed in the end-tidal
concentration of desflurane between the two groups
(Figure 2). There was statistically significant correlation
between the end-tidal concentration of desflurane at the
stop of remifentanil and awake time (P = 0.002). No sig-








30 min 50 (0–100) 20 (0–80) 0.002
2 h 40 (20–80) 30 (10–60) 0.018
6 h 30 (20–50) 30 (20–50) 0.966
12 h 27 (20–40) 26 (10–60) 0.593
24 h 20 (0–40) 18 (10–30) 0.330
Rescue analgesics, n 3 (2–3) 2 (1–3) 0.039
First use of rescue analgesics (min) 32 (10–72) 32 (5–417) 0.742
Values are given as median (range). A group: no tapering group, B group:
tapering group; NRS: numerical rating scale (0 = no pain, 100 = the worst
possible pain).events including nausea, vomiting, shivering, headache,
dizziness and drowsiness after surgery (Table 3).
Discussion
This study was designed to assess whether intraoperative
tapering of remifentanil could diminish pain and rescue
analgesics postoperatively. The results of this study
showed that stepwise tapering of remifentanil at the end
of the surgery reduced the postoperative pain scores and
the requirement of rescue analgesics.
Patients in control group showed higher pain scores
and required more rescue analgesics than those in taper-
ing group did during immediate postoperative period.
The possible explanation for this finding may be the de-
velopment of opioid induced hyperalgesia or acute opi-
oid tolerance. Opioid induced hyperalgesia is defined by
the increased sensitivity by pain whereas acute opioid
tolerance is a decreased sensitivity to opioid analgesics
after administration of high dose opioids [6]. However, it
is difficult to discriminate acute opioid tolerance and
opioid induced hyperalgesia since a mixture of these
phenomena may be associated with the infusion of high-
dose opioids [13]. In addition, both phenomena are
known to be induced by the activation of the NMDA re-
ceptor and the subsequent central sensitization of noci-
ceptive system [8]. One of the current review of clinical
data suggested that increased postoperative pain scores
and subsequent greater requirement of analgesics may
be associated with acute opioid tolerance, and the
greater demand of opioids at a later recovery stage could
be related with opioid induced hyperalgesia after high-
dose remifentanil anesthesia [14].
Remifentanil differs from other opioids in that it dir-
ectly acts on NMDA receptor [15]. Glycine, a vehicle of
remifentanil, is bound with glutamate of the NMDA re-
ceptor during activation [16]. The present study showed
clinically that stepwise tapering of remifentanil at the
end of surgery reduced the postoperative pain.
Remifentanil is a short-acting opioid with a predictable
rapid recovery [1]. In the current study, high-dose remifen-
tanil (0.3 μg/kg/min) was used throughout the operation
before intervention. Then, patients with control group were
maintained with 0.3 μg/kg/min remifentanil until the end
of surgery whereas patients with tapering group received
titration of remifentanil (0.3 - > 0.2- > 0.1 μg/kg/min) for
at least 30 minutes. Several previous investigation on opi-
oid induced hyperalgesia infused high dose of remifentanil
from 0.2 -0.4 μg/kg/min [2,3,17]. Guignard et al. [2], eval-
uated postoperative pain scores in patients after major ab-
dominal surgery who had received high-dose remifentanil
(mean dose 0.3 μg/kg/min) perioperatively and found that
patients with high-dose remifentanil anesthesia needed
morphine earlier and greater doses to achieve satisfactory
analgesia postoperatively. In the study by Schmidt et al.,
Figure 2 End-tidal concentration of desflurane during the operation. Values are given as mean (SD). A group: no tapering group, B group:
tapering group.
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(0.4 μg/kg/min) or a low (0.1 μg/kg/min) dose of remifen-
tanil and reported opioid-induced hyperalgesia [17]. Surgi-
cal site pain was assessed and postoperative values were
compared with preoperative baseline measurements at
other sites with cold and cold pressor test at 30 and
90 min after discontinuation of remifentanil [17]. Previous
investigation of patients undergoing major abdominal sur-
gery suggested hyperalgesia after high dose remifentanil
and preventive effect of ketamine for opioid-induced
hyperalgesia [3]. Patients with intraoperative high-dose
remifentanil (0.4 μg/kg/min) showed larger areas of hyper-
algesia surrounding the wound and the request of higher
doses of postoperative opioid for pain control [3]. On theTable 3 Awakening time and postoperative adverse
events
Treatment Groups
A group (n = 27) B group (n = 30) P value
Awakening time (min) 6 (1–15) 4 (2–14) 0.086
Nausea 7 (26) 6 (20) 0.594
Vomiting 1 (4) 1 (3) 1.000
Shivering 3 (11) 3 (10) 1.000
Headache 12 (44) 9 (30) 0.259
Dizziness 2 (7) 8 (27) 0.083
Drowsiness 1 (4) 0 (0) 0.474
Values are given as median (range) or number of patients (%). A group: no
tapering group, B group: tapering group. Awakening time: the time interval
from remifentanil discontinuation to extubation.other hand, patients with low-dose remifentanil (0.05 μg/
kg/min) alone, or higher-dose remifentanil and ketamine,
reported similar areas of hyperalgesia and required similar
doses of postoperative morphine [3]. In the study of com-
paring the effects of ketamine and paracetamol on pre-
venting remifentanil induced hyperalgesia, anesthesia was
maintained with 0.4 μg/kg/min remifentanil infusion in all
groups and it was shown that ketamine and paracetamol
were both effective in preventing remifentanil induced
hyperalgesia [18].
Previous investigations with various anesthetics re-
ported that anesthetics also affect opioid induced hyper-
algesia since anesthetics have NMDA antanogist effect.
Propofol suppresses NMDA receptor and there is a pos-
sibility of confusion for the interpretation of the results
[19,20]. Therefore, balanced anesthesia with desflurane-
high dose remifentanil was used for this study [21]. The
concentration of desflurane was adjusted to maintain the
spectral entropy between 40 and 60 and there was no
difference in the end-tidal concentration of desflurane
between the two groups.
A few limitations should be considered. The first limita-
tion is the dose of remifentanil infusion during interven-
tion. There was no established tapering regimen and the
dose of remifentanil was stepwise reduced for at least
30 minutes (0.3 μg/kg/min for 10 minutes→ 0.2 μg/kg/
min for 10 minutes→ 0.1 μg/kg/min for at least 10 mi-
nutes) based on the previous animal experiment [11]. Sec-
ond, NSAID was used as a rescue analgesic instead of
opioids in this study since patients with thyroidectomy
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Therefore, it is insufficient to explain the result of this
study as opioid induced hyperalgesia. Third, only post-
operative pain score was assessed without direct measure-
ment of somatosensory threshold after anesthesia.
Postoperative surgical site pain should have been assessed
and compared with preoperative value. In addition, post-
operative surgical site pain should have been compared
with those of other sites with cold and cold pressor test
after discontinuation of remifentanil. Thyroidectomy was
chosen in this study because balanced anesthesia with
inhalation agent and remifentanil is used for the mainten-
ance of anesthesia. During thyroidectomy, tracheal stimu-
lation with endotracheal cuff pressure needs adequate
depth of anesthesia with high dose of remifentanil. How-
ever, it is difficult to detect statistical difference between
the two groups after postoperative 2 hr and this
phenomenon seems to be related with lesser degree of
pain after thyroidectomy (10–30 NRS). It remains to be
seen whether increased pain scores could be associated
with hyperalgesia and further study is needed to evaluate
effect of tapering of remifentanil on the opioid induced
hyperalgesia with direct measurement of somatosensory
threshold before and after anesthesia.
Conclusion
In conclusion, the results of this study suggested that
stepwise tapering of remifentanil at the end of surgery
could decrease postoperative pain and rescue analgesics
after desflurane-high dose remifentanil anesthesia in
patients with thyroidectomy. The further study on the
exact mechanism of this phenomenon is needed.
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